501674-22-2

Basic information

• Product Name: 1-BOC-4-[(3,4-DIFLUOROPHENYL)AMINO]-PIPERIDINE
• Synonyms: 1-BOC-4-[(3,4-DIFLUOROPHENYL)AMINO]-PIPERIDINE
• CAS NO: 501674-22-2
• Molecular Formula: C₁₆H₂₂F₂N₂O₂
• Molecular Weight: 312.358
• Mol File: 501674-22-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-[(3,4-DIFLUOROPHENYL)AMINO]-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-[(3,4-DIFLUOROPHENYL)AMINO]-PIPERIDINE(501674-22-2)
• EPA Substance Registry System: 1-BOC-4-[(3,4-DIFLUOROPHENYL)AMINO]-PIPERIDINE(501674-22-2)

Safety Data

• Hazardous Substances Data: 501674-22-2(Hazardous Substances Data)

Usage

Chemical structure

A piperidine ring with a BOC protecting group at the nitrogen atom and a difluorophenylamino group attached to the piperidine ring.

Common use

Intermediate in organic synthesis, particularly in the preparation of pharmaceutical drugs.

BOC protecting group function

Blocks the reactivity of the amine group, allowing for selective manipulation of the piperidine ring.

Potential applications

Development of new drugs, as the presence of the difluorophenylamino group can enhance the pharmacological properties of a molecule.

Versatility

A valuable compound in medicinal chemistry and drug discovery.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 3863-11-4 3,4-difluoroaniline 

Downstream Products

• 501674-25-5 1-(tert-Butoxycarbonyl)-4-[N-(3,4-difluorophenyl)-N-[[3-(3,4,5-trimethoxyphenyl)pyridin-5-yl]methyl]amino]piperidine 
• 501674-27-7 1-(tert-Butoxycarbonyl)-4-[N-(3,4-difluorophenyl)-N-[3-(3,4,5-trimethoxyphenyl)benzyl]amino]piperidine 
• 356557-95-4 (3,4-Difluoro-phenyl)-piperidin-4yl-amine 

Relevant articles and documents

Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease

Development of multitargeted ligands have demonstrated remarkable efficiency as potential therapeutics for Alzheimer's disease (AD). Herein, we reported a new series of deoxyvasicinone analogues as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by 1HNMR, 13CNMR and mass spectrometry. All the synthesized compounds 11(a-j) and 15(a-g) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. All the screened compounds possessed weak inhibition of BACE-1, Aβ42 and α-syn aggregation. However, several compounds were identified as potential hits in the AChE inhibitory screening assay and cellular tau aggregation screening. Among all compounds, 11f remarkably inhibited AChE activity and cellular tau oligomerization at single-dose screening (10 μM). Moreover, 11f displayed a half-maximal inhibitory concentration (IC50) value of 0.91 ± 0.05 μM and half-maximal effective concentration (EC50) value of 3.83 ± 0.51 μM for the inhibition of AChE and cellular tau oligomerization, respectively. In addition, the neuroprotective effect of 11f was determined in tau-expressing SH-SY5Y cells incubated with Aβ oligomers. These findings highlighted the potential of 11f to function as a multifunctional ligand for the development of promising anti-AD drugs.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group;W1 and W2 each independently represent N or CH;X represents O, NR4, CONR4 or NR4CO;R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; andl, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Cyclic amine compounds and pharmaceutical composition containing the same

A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.